A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma

Trial Profile

A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs AMG 232 (Primary) ; Dabrafenib; Trametinib
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 14 Feb 2018 Planned primary completion date changed from 15 Apr 2018 to 15 Oct 2019.
    • 14 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Jul 2017 Planned End Date changed from 1 Jun 2021 to 17 Aug 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top